Aslanova Minira, Yu Eun-Mi, Aragon-Ching Jeanny B
Division of Hematology and Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA.
GU Medical Oncology, Inova Schar Cancer Institute, Fairfax, VA 22031, USA.
Explor Target Antitumor Ther. 2024;5(4):971-980. doi: 10.37349/etat.2024.00258. Epub 2024 Jul 29.
The landscape of treatment for first-line therapy in advanced urothelial cancer (aUC) and metastatic urothelial cancer (mUC) has rapidly changed in the last year alone. Maintenance avelumab remains a viable treatment option for many patients across the globe for those who have responded or have achieved stable disease after platinum-based chemotherapy. However, the recent FDA approvals based on EV-302 for enfortumab vedotin (EV) and pembrolizumab, as well as CheckMate-904 with gemcitabine and cisplatin with nivolumab (GC+N) followed by maintenance nivolumab have left clinicians with the complicated decision of determining which regimen is most appropriate for their individual patients with untreated aUC. This commentary highlights the key trials that have set the standard-of-care for front-line aUC treatment and suggestions for choosing different regimens for the appropriate patient.
仅在过去一年中，晚期尿路上皮癌（aUC）和转移性尿路上皮癌（mUC）一线治疗的格局就迅速发生了变化。对于那些在铂类化疗后有反应或病情稳定的全球许多患者来说，维持使用阿维鲁单抗仍然是一种可行的治疗选择。然而，最近美国食品药品监督管理局（FDA）基于EV-302试验批准了恩杂鲁胺（EV）和帕博利珠单抗，以及吉西他滨和顺铂联合纳武单抗（GC+N）随后维持使用纳武单抗的CheckMate-904试验，这让临床医生在决定哪种方案最适合未治疗的aUC个体患者时面临复杂的抉择。本评论重点介绍了为一线aUC治疗设定护理标准的关键试验，以及为合适患者选择不同方案的建议。
